A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)
机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital &Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road,Guangzhou 510080, Guangdong, China广东省人民医院[2]Nanjing General Hospital of NanjingMilitary Command, Nanjing, Jiangsu, China[3]Zhongshan Hospital, Shanghai,China[4]The Tumor Hospital affiliated to Harbin Medical University, Harbin,Heilongjiang, China[5]General Hospital of Tianjin Medical University, Heping,Tianjin, China[6]The Affiliated Hospital of Qingdao University, Qingdao,Shandong, China[7]Sichuan Cancer Hospital, Chengdu, Sichuan, China四川省肿瘤医院[8]Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China浙江省肿瘤医院[9]Hunan CancerHospital, Changsha, Hunan, China[10]Chinese PLA General Hospital, Beijing,China[11]The People’s Hospital of Guangxi Zhuang Autonomous Region,Nanning, Guangxi, China[12]Shanxi Cancer Hospital, Taiyuan, Shanxi, China[13]Lilly Suzhou Pharmaceutical Co,Ltd, Shanghai, China
Background: In recent years, systemic chemotherapy and molecular targeted therapy have become standard firstline treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC). The objective of this survey was to investigate first-line anticancer treatment patterns and gene aberration test status of patients with advanced nonsquamous NSCLC in China. Methods: Patients included in this study had unresectable Stage IIIB/IV nonsquamous NSCLC and were admitted during August 2015 to March 2016 into one of 12 tertiary hospitals throughout China for first-line anticancer treatment. Patient data (demographics, NSCLC histologic type, Eastern Cooperative Oncology Group [ECOG] Performance Status [PS], gene aberration test and results [if performed], and first-line anticancer treatment regimen) were extracted from medical charts and entered into Medical Record Abstraction Forms (MERAFs), which were collated for analysis. Results: Overall, 1041 MERAFs were collected and data from 932 MERAFs were included for analysis. Patients with unresectable Stage IIIB/IV nonsquamous NSCLC had a median age of 59 years, 56.4% were male, 58.2% were never smokers, 95.0% had adenocarcinoma, and 92.9% had an ECOG PS <= 1. A total of 665 (71.4%) patients had gene aberration tests; 46.5% (309/665) had epidermal growth factor receptor (EGFR) gene mutations, 11.5% (48/416) had anaplastic lymphoma kinase (ALK) gene fusions, and 0.8% (1/128) had a c-ros oncogene 1 gene fusion. The most common first-line treatment regimen for unresectable Stage IIIB/IV nonsquamous NSCLC was chemotherapy (72.5%, 676/932), followed by tyrosine kinase inhibitors (TKIs; 26.1%, 243/932), and TKIs plus chemotherapy (1.4%, 13/932). Most chemotherapy regimens were platinum-doublet regimens (93.5%, 631/676) and pemetrexed was the most common nonplatinum chemotherapy-backbone agent (70.2%, 443/631) in platinum-doublet regimens. Most EGFR mutationpositive patients (66.3%, 205/309) were treated with EGFR-TKIs. Conclusions: Findings from our survey of 12 tertiary hospitals throughout China showed an increased rate of gene aberration testing, compared with those rates reported in previous surveys, for patients with advanced nonsquamous NSCLC. In addition, pemetrexed/platinum-doublet chemotherapy was the predominant first-line chemotherapy regimen for this population. Most patients were treated based on their gene aberration test status and results.
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong General Hospital &Guangdong Academy of Medical Sciences, 106 Zhongshan 2nd Road,Guangzhou 510080, Guangdong, China
通讯作者：
推荐引用方式(GB/T 7714)：
Qing Zhou,Yong Song,Xin Zhang,et al.A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)[J].BMC CANCER.2017,17:doi:10.1186/s12885-017-3451-x.
APA：
Qing Zhou,Yong Song,Xin Zhang,Gong-Yan Chen,Dian-Sheng Zhong...&Yi-Long Wu.(2017).A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).BMC CANCER,17,
MLA：
Qing Zhou,et al."A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)".BMC CANCER 17.(2017)
医学